Propylene Glycol

Propylene Glycol

SCHEMBL3670673

C=CCOC(=O)C(=C)C.CC(O)CO.CCOCC

nearest known ligand 0.47

Full drug profile on Sugi Atlas →

Known targets — ChEMBL curated mechanism

SLC5A2

The experimentally established mechanism targets of Propylene Glycol. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.

Predicted protein targets (top 13)

geneUniProtsupporting neighboursconfidence
THRB P10828 1/20 0.47
TSHR P16473 5/20 0.42
TDP1 Q9NUW8 2/20 0.38
ALDH1A1 P00352 2/20 0.32
CYP2D6 P10635 1/20 0.30
CYP2C19 P33261 1/20 0.30
CYP3A4 P08684 2/20 0.30
MAPT P10636 2/20 0.30
USP2 O75604 1/20 0.30
LMNA P02545 1/20 0.30
RECQL P46063 1/20 0.30
SMN1; SMN2 Q16637 1/20 0.30
CYP2C9 P11712 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Glycerin SCHEMBL1862655 0.91 THRB (0.47) THRBTSHRTDP1ALDH1A1CYP2D6
Ether SCHEMBL956738 0.90 THRB (0.46) THRBTSHRTDP1ALDH1A1MAPT
Ether SCHEMBL173935 0.89 THRB (0.58) THRBTSHRTDP1ALDH1A1CYP3A4
Ether SCHEMBL2865262 0.87 THRB (0.53) THRBTSHRTDP1ALDH1A1CYP3A4
Propylene Glycol SCHEMBL8605999 0.86 TDP1 (0.41) THRBTSHRTDP1ALDH1A1CYP3A4
Propylene Glycol SCHEMBL243614 0.86 TDP1 (0.41) THRBTSHRTDP1ALDH1A1CYP3A4
Ether SCHEMBL2148363 0.84 THRB (0.50) THRBTSHRTDP1ALDH1A1CYP3A4
1,3-Butanediol SCHEMBL10562993 0.81 TSHR (0.44) THRBTSHRTDP1ALDH1A1CYP3A4
Propylene Glycol SCHEMBL3669314 0.81 TSHR (0.44) THRBTSHRTDP1ALDH1A1CYP3A4
Propylene Glycol SCHEMBL460711 0.81 TDP1 (0.46) TSHRTDP1ALDH1A1CYP3A4MAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-106170472-B Inhibitor combination for lithium salt catalyzed transesterification process and method for removing lithium salt 陶氏环球技术有限责任公司 2020-04-14 CN disclosed
US-20180037531-A1 Inhibitor Combination for Lithium Salt-Catalyzed Transesterification Process and Method for Removing Lithium Salt DOW GLOBAL TECHNOLOGIES LLC (US) 2018-02-08 US disclosed
US-9796650-B2 Inhibitor combination for lithium salt-catalyzed transesterification process and method for removing lithium salt DOW GLOBAL TECHNOLOGIES LLC (US) 2017-10-24 US disclosed
EP-3087049-A1 INHIBITOR COMBINATION FOR LITHIUM SALT-CATALYZED TRANSESTERIFICATION PROCESS AND METHOD FOR REMOVING LITHIUM SALT Dow Global Technologies Llc (US) 2016-11-02 EP disclosed
US-20160297736-A1 Inhibitor Combination for Lithium Salt-Catalyzed Transesterification Process and Method for Removing Lithium Salt DOW GLOBAL TECHNOLOGIES LLC 2016-10-13 US disclosed
WO-2015099915-A1 INHIBITOR COMBINATION FOR LITHIUM SALT-CATALYZED TRANSESTERIFICATION PROCESS AND METHOD FOR REMOVING LITHIUM SALT DOW GLOBAL TECHNOLOGIES LLC (US) 2015-07-02 WO disclosed
EP-2218724-B1 EPOXY GROUP-CONTAINING ORGANOSILOXANE COMPOUND, CURABLE COMPOSITION FOR TRANSFER MATERIAL, AND FINE PATTERN FORMING METHOD USING THE COMPOSITION SHOWA DENKO KK (JP) 2015-01-07 EP disclosed
US-8604150-B2 Epoxy group-containing organosiloxane compound, curable composition for transfer materials and method for forming micropattern using the composition SHOWA DENKO K.K. (JP) 2013-12-10 US disclosed
US-20100258983-A1 EPOXY GROUP-CONTAINING ORGANOSILOXANE COMPOUND, CURABLE COMPOSITION FOR TRANSFER MATERIALS AND METHOD FOR FORMING MICROPATTERN USING THE COMPOSITION SHOWA DENKO K.K. (JP) 2010-10-14 US disclosed
EP-2218724-A1 EPOXY GROUP-CONTAINING ORGANOSILOXANE COMPOUND, CURABLE COMPOSITION FOR TRANSFER MATERIAL, AND FINE PATTERN FORMING METHOD USING THE COMPOSITION Showa Denko K.K. (JP) 2010-08-18 EP disclosed
WO-2008091114-A1 PHOTO-CURABLE COMPOSITION HAVING INHERENTLY EXCELLENT RELEASING PROPERTY AND PATTERN TRANSFER PROPERTY, METHOD FOR TRANSFERRING PATTERN USING THE COMPOSITION AND LIGHT RECORDING MEDIUM HAVING POLYMER PATTERN LAYER PRODUCED USING THE COMPOSITION SAMSUNG ELECTRONICS CO., LTD. (KR) 2008-07-31 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20160297736-A1 Inhibitor Combination for Lithium Salt-Catalyzed Transesterification Process and Method for Removing Lithium Salt ADH1C, ADH1A, MAP2K1 THRB 576/4885TSHR 3806/4885TDP1 3776/4885
US-20180037531-A1 Inhibitor Combination for Lithium Salt-Catalyzed Transesterification Process and Method for Removing Lithium Salt ADH1C, ADH1A, MAP2K1 THRB 576/4885TSHR 3806/4885TDP1 3776/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.